Every 8-K that Io Biotech, Inc. (IOBT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IOBT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IOBT filings page.
IO Biotech, Inc. has ceased operations and filed a voluntary Chapter 7 bankruptcy petition in the U.S. Bankruptcy Court for the District of Delaware on March 31, 2026. A Chapter 7 trustee will take control of the company, liquidate assets, and pay creditors according to the Bankruptcy Code.
The company states it is unlikely that holders of its common stock will receive any payment or distribution from the bankruptcy proceedings. The filing triggers an event of default under a finance contract with the European Investment Bank, and all directors, officers, and employees have resigned or been terminated. IO Biotech will no longer be able to prepare or file its required SEC reports.
IO Biotech, Inc. reported that Nasdaq has notified the company it is not meeting the Nasdaq Global Select Market requirement that market value of listed securities be at least $50 million for 30 consecutive business days. This follows IO Biotech’s market value staying below that threshold.
The company has 180 calendar days, until August 11, 2026, to regain compliance. Nasdaq will consider the company compliant again if its market value of listed securities is at or above $50 million for at least ten consecutive business days during this period.
If IO Biotech does not regain compliance by the deadline, Nasdaq may initiate delisting of its common stock, though the company would have the opportunity to appeal under Nasdaq’s procedures. The notice does not immediately affect trading of IO Biotech’s shares, which continue on the Nasdaq Global Select Market.
IO Biotech, Inc. reported that its board approved a restructuring and workforce reduction plan intended to significantly cut operating expenses while the company explores a range of strategic alternatives. The plan is expected to result in a significant global reduction of the company’s workforce.
The company expects to incur one-time charges and cash expenditures of approximately $2.4 million to $2.6 million, mainly for wages, severance, healthcare continuation, earned vacation and related termination costs, primarily during the first quarter of 2026. IO Biotech also notified Chief Medical Officer Qasim Ahmad, M.D., a named executive officer, that his employment will end on February 15, 2026.
The company announced it has retained Raymond James & Associates, Inc. as exclusive financial advisor to assist in its ongoing exploration of strategic alternatives, and issued a press release describing the restructuring and workforce reduction plan, which is attached as an exhibit.
IO Biotech, Inc. filed a current report stating that on January 21, 2026 it issued a press release announcing that it plans to explore strategic alternatives. This means the company is formally beginning a review of potential options for its future direction, which can range from continuing its current plan to considering significant corporate changes, depending on what the review determines. The press release describing this process is attached as an exhibit to the report.
IO Biotech, Inc. reported that its Senior Vice President and Chief Accounting Officer, Brian Burkavage, has informed the company of his intent to resign effective December 12, 2025 to pursue another opportunity. The company stated that his resignation is not due to any dispute or disagreement with the company.
The company’s Chief Financial Officer, Amy Sullivan, has been designated as IO Biotech’s principal accounting officer, effective upon Mr. Burkavage’s departure. Her background is described in the company’s 2025 definitive proxy statement. IO Biotech noted that no new compensatory arrangements will be entered into with Ms. Sullivan in connection with her additional role.
IO Biotech, Inc. announced that it will participate in the Jefferies Global Healthcare Conference beginning on November 18, 2025. In connection with this event, the company prepared an updated corporate investor presentation that it plans to use at the conference and in meetings with investors.
The updated investor presentation, referred to as the Investor Deck, was posted to the company’s website on November 18, 2025 and is also provided as an exhibit to this report. The company notes that this material is being furnished rather than filed under U.S. securities laws.
IO Biotech, Inc. (IOBT) furnished an 8-K announcing it issued a press release with financial results for the fiscal quarter ended September 30, 2025 and an operations update. The press release is attached as Exhibit 99.1.
The company states the information under Item 2.02 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically referenced.
IO Biotech, Inc. reported that its board approved a major restructuring and workforce reduction plan to conserve capital and focus on developing Cylembio. The plan will cut approximately 50% of the company’s global workforce.
The company expects to record one-time charges of about $1.0 million to $1.5 million, mainly for severance, continued healthcare, earned vacation and related termination costs, largely in the third quarter of 2025, with payments expected to be completed by the fourth quarter of 2025.
IO Biotech also disclosed that the FDA has recommended it not submit a BLA based on data from the IOB-013 clinical trial, which showed improved progression-free survival for Cylembio plus pembrolizumab but narrowly missed statistical significance. The company plans further discussions with the FDA and European regulators on an additional potential registrational study and possible paths to approval in the United States and European Union.
IO Biotech, Inc. filed a current report to note that it has released its financial results for the fiscal quarter ended June 30, 2025. The company issued a press release on August 14, 2025 sharing quarterly results and providing an update on its operations for the same period.
The press release is included as Exhibit 99.1 and is being furnished rather than filed, which means it is not automatically subject to certain Exchange Act liabilities or incorporated into other SEC filings unless specifically referenced.
IO Biotech disclosed topline results from its Phase 3 IOB-013 study evaluating Cylembio plus pembrolizumab versus pembrolizumab alone as first-line treatment for unresectable or metastatic melanoma. The randomized trial enrolled 407 patients (203 combination, 204 monotherapy). The primary endpoint, progression-free survival assessed by blinded independent review per RECIST v1.1, showed early and sustained separation with a hazard ratio (HR) of 0.77 (95% CI: 0.58–1.00; p=0.056), and median PFS of 19.4 months versus 11.0 months. The primary result falls short of the prespecified significance threshold.
Notable subgroup findings include a pronounced benefit in PD-L1 negative tumors (HR 0.54; mPFS 16.6 vs 3.0 months; nominal p=0.006) and in patients without prior anti–PD-1 therapy (post hoc HR 0.74; mPFS 24.8 vs 11.0 months; nominal p=0.037). Overall survival trends were favorable but immature (HR 0.79; 95% CI: 0.57–1.10). The combination was generally well tolerated; injection site reactions were most common (reported in 56% of combination arm patients) and resolved on treatment. The company plans regulatory discussions about a potential BLA and will present more detailed data. It disclosed an estimated cash balance of approximately $28.1 million plus a €12.5 million tranche drawn under a term loan, which it expects to fund operations into the first quarter of 2026, subject to final close procedures.
IO Biotech (Nasdaq: IOBT) filed an 8-K announcing that it has met the conditions to draw the €12.5 million Tranche B of its previously disclosed €57.5 million term-loan facility with the European Investment Bank (EIB).
In exchange, the EIB received a warrant to purchase up to 4,221,867 shares of common stock at a strike price of $1.3159. The drawdown is expected on or about July 4, 2025.
- The warrant and the underlying shares were issued in a private placement relying on Section 4(a)(2).
- Key warrant terms are unchanged from the December 20 2024 filing.
The transaction bolsters near-term liquidity but introduces potential dilution for existing shareholders.
IO Biotech, Inc. (Nasdaq: IOBT) filed a Form 8-K to disclose an Addendum to the 2017 service agreement with Chief Executive Officer Mai-Britt Zocca, Ph.D. The addendum, executed 19 June 2025 by subsidiary IO Biotech ApS, formalises severance and change-in-control protections.
Standard Qualifying Termination (without cause or by the CEO for good reason) entitles the CEO to:
- Cash severance equal to 12 months of current base salary.
- Pro-rated annual bonus for the year of termination, calculated on actual performance.
- Any unpaid prior-year bonus.
- Accelerated vesting of equity awards scheduled to vest within 12 months after termination, with performance awards vesting on actual results.
Change-in-Control (CIC) Protection: If a Qualifying Termination occurs within six months before or 12 months after a CIC, (i) cash severance increases to 18 months of base salary, (ii) the current-year bonus is paid at full, non-prorated value, and (iii) 100 % of outstanding equity vests immediately, with performance goals deemed met at target or as otherwise specified in award agreements.
All payments are contingent on execution and non-revocation of a general release of claims. The company attached the Addendum as Exhibit 10.1; no other financial statements or exhibits were included.
The disclosure does not alter current operations or financial guidance but increases potential cash outflows and equity dilution in a termination or CIC scenario. Investors should note the enhanced protection may aid retention during strategic discussions but could represent a modest cost if triggered.